维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

已收盘 12-16 16:08:20

51.550

-0.450

-0.87%

最高52.000	最低49.060	成交量54.10万
今开51.900	昨收52.000	日振幅5.65%
总市值102.58亿	流通市值78.87亿	总股本1.99亿
成交额2,747万	换手率0.35%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":51.55,"timestamp":1765872500007,"preClose":52,"halted":0,"volume":541008,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盘","change":-0.45,"latestTime":"12-16 16:08:20","open":51.9,"high":52,"low":49.06,"amount":27470217,"amplitude":0.056538,"askPrice":51.55,"askSize":5400,"bidPrice":51.1,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":52,"openAndCloseTimeList":[[1765848600000,1765857600000],[1765861200000,1765872000000]],"volumeRatio":1.065418,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/wiki","defaultTab":"wiki","newsList":[{"id":"2591764679","title":"维立志博-B(09887)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2591764679","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591764679?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:42","pubTimestamp":1765802564,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年12月15日，本公司已就拟实施H股全流通(H股全流通)向中国证监会提交备案材料，以转换合共4439.16万股本公司未上市股份(未上市股份)为本公司H股(占于本公告日期本公司已发行股本总额1.99亿股股份约22.32%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161","09887"],"gpt_icon":0},{"id":"2591264799","title":"每日卖空追踪 | 维立志博-B 12月15日卖空量成交1.86万股，卖空比例为6.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264799?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787440,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月15日，跌2.35%，卖空量成交1.86万股，较上一交易日减少51.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163643a6a45a4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163643a6a45a4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"2591686849","title":"每日卖空追踪 | 维立志博-B 12月12日卖空量成交2.47万股，卖空比例为7.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686849","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591686849?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528239,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月12日，涨0.47%，卖空量成交2.47万股，较上一交易日减少56.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165851a4446e77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165851a4446e77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"gpt_icon":0},{"id":"2590333510","title":"智通港股投资日志|12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2590333510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590333510?lang=zh_cn&edition=full","pubTime":"2025-12-12 00:00","pubTimestamp":1765468803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年12月12日，港股上市公司投资日志如下：    类别 公司  新股活动智汇矿业(招股中)希迪智驾(招股中)HASHKEY HLDGS(招股中) 业绩公布日日光控股靛蓝星 股东大会召开日浩柏国际中食民安信利国际泸州银行深圳高速公路股份维立志博-B三花智控玄武云中信国际电讯诺科达科技 分红派息港通控股（除净日）完美医疗（除净日）义合控股（除净日）亚洲联合基建控股（除净日）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2590213105","title":"维立志博-B12月11日遭主力抛售80.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590213105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590213105?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440952,"startTime":"0","endTime":"0","summary":"12月11日, 维立志博-B股价跌1.03%，报收53.00元，成交金额2185.8万元，换手率0.27%，振幅5.14%，量比0.59。维立志博-B今日主力资金净流出80.9万元，上一交易日主力净流出237.3万元。该股近5个交易日上涨0.19%，主力资金累计净流入52.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出108.9万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162105a6990c8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162105a6990c8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"2590390894","title":"港股异动 | 维立志博-B(09887)涨超3% LBL-034突破性数据于2025 ASH年会口头报告发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590390894","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590390894?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:37","pubTimestamp":1765262240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超3%，截至发稿，涨2.39%，报53.6港元，成交额5125.77万港元。消息面上，维立志博-B发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤的GPRC5D/CD3双特异性抗体LBL-034在大会首日第一个进行口头报告。2024年10月LBL-034获得FDA的孤儿药认定，用于治疗多发性骨髓瘤。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000500386.USD","ASH","BK4109","HK0000252152.HKD","BK1161","HK0000252160.HKD","LU2463526074.USD"],"gpt_icon":0},{"id":"2590357319","title":"每日卖空追踪 | 维立志博-B 12月08日卖空量成交4.08万股，卖空比例为5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590357319?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182639,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月08日，涨1.26%，卖空量成交4.08万股，较上一交易日减少20.47%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163636979615dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163636979615dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","BK1161","09887","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2590357391","title":"ASH伴髓外病变ORR 100%，维立志博LBL-034或改写多发性骨髓瘤治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357391","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590357391?lang=zh_cn&edition=full","pubTime":"2025-12-08 14:54","pubTimestamp":1765176840,"startTime":"0","endTime":"0","summary":"TCE赛道产业爆发，应用边界不断延伸，技术持续迭代。在今年的ASH年会上，维立志博的条件性激活的GPRC5D/CD3双抗LBL-034，凭借颠覆多发性骨髓瘤治疗的潜力，入选ASH年会首场口头汇报的首个重磅议题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","HK0000252152.HKD","09887"],"gpt_icon":0},{"id":"2589871029","title":"维立志博-B(09887)：LBL-034临床数据于第67届ASH年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871029","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589871029?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:28","pubTimestamp":1765103333,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤的GPRC5D/CD3双特异性抗体LBL-034在大会首日第一个进行口头报告。LBL-034的主要临床亮点包括：LBL-034剂量递增至1,200μg/kg，未观察到任何剂量限制性毒性，未达到最大耐受剂量。与生活质量密切相关不良事件均为1至2级，多数不良事件发生于第一周期，在后续治疗中的发生率显著降低，不影响治疗连续性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","LU2463526074.USD","BK4109","09887","BK1161"],"gpt_icon":1},{"id":"2588838525","title":"每日卖空追踪 | 维立志博-B 12月04日卖空量成交4.02万股，卖空比例为7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588838525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588838525?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837041,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月04日，跌0.94%，卖空量成交4.02万股，较上一交易日减少80.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2588039756","title":"已达成超10亿美元合作，维立志博自免1类新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2588039756","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588039756?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:32","pubTimestamp":1764631937,"startTime":"0","endTime":"0","summary":"近日，中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2588382740","title":"维立志博-B(09887)：LBL-047取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588382740?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:32","pubTimestamp":1764577967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年11月25日，其自主研发候选药物LBL-047的新药临床试验申请已获中国国家药品监督管理局批准。目前全球范围内尚无同时靶向浆细胞样树突状细胞及B细胞的药物获批临床试验。LBL-047凭借此独特作用机制，具备同类第一及同类最优的潜力。其将评估LBL-047的安全性、耐受性及其在SLE患者中的初步临床有效性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","IND","HK0000500386.USD","09887"],"gpt_icon":0},{"id":"2588471777","title":"每日卖空追踪 | 维立志博-B 12月01日卖空量成交3.08万股，卖空比例为6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588471777","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588471777?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577840,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月01日，跌0.94%，卖空量成交3.08万股，较上一交易日减少24.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"1196990754","title":"南京维立志博(9887)临时股东大会将审议H股奖励计划等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1196990754","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196990754?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:17","pubTimestamp":1764339460,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司(股份代号：9887)将于2025年12月17日上午十时在中国南京市嘉陵江东街18号3幢8层召开临时股东大会，大会将以投票方式审议特别决议案，包括采纳H股奖励计划、授权董事会及/或代表办理相关事宜，以及就最多不超过已发行股份5%的新股配发申请上市。\n此外，还将表决服务供应商分项限额、取消监事会及修订公司章程等事项。更多详情可查阅香港联交所网站（www.hkexnews.hk）及公司网站（www.leadsbiolabs.com）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2586214365","title":"速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2586214365","media":"医药观澜","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586214365?lang=zh_cn&edition=full","pubTime":"2025-11-27 11:41","pubTimestamp":1764214913,"startTime":"0","endTime":"0","summary":"中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","HK0000500386.USD","BK1161","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"2586252169","title":"每日卖空追踪 | 维立志博-B 11月26日卖空量成交4900股，卖空比例为1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586252169?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145838,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月26日，涨3.2%，卖空量成交4900股，较上一交易日减少93.61%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161","09887"],"gpt_icon":0},{"id":"2586712044","title":"维立志博-B(09887)建议采纳H股奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2586712044","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586712044?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:48","pubTimestamp":1764082115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年11月25日审议批准建议采纳H股奖励计划。H股奖励计划旨在：促进实现公司长远可持续发展及业绩目标;把受让人的利益与股东、投资者及公司的利益紧密联系起来，从而增强公司凝聚力，促进公司实现最大价值;及完善公司激励机制，以吸引、激励及留聘对公司持续经营、发展及长远增长贡献良多的集团董事、高级管理层及雇员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"2586499055","title":"2025中国TCE赛道全景：百余管线竞逐，谁将领跑免疫治疗新纪元？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499055","media":"ITBEAR科技资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586499055?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:06","pubTimestamp":1763978796,"startTime":"0","endTime":"0","summary":"与ADC依赖细胞毒素杀伤肿瘤细胞不同，TCE通过激活免疫系统实现治疗，对靶点表达量的要求较低，但对肿瘤特异性要求更高。在血液瘤领域，TCE已取得显著成果。截至2025年7月，全球已有9款TCE双抗获批上市，覆盖多发性骨髓瘤、弥漫大B淋巴瘤等多个适应症，市场规模超百亿美元。其CD19/BCMA/CD3三抗LBL-051通过NewCo模式与Aditum Bio合作，交易总额达6.14亿美元，创下国内临床前TCE管线授权纪录。平台型药企在TCE领域的优势日益凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1587","BK1574","09887","BK1161","02162"],"gpt_icon":0},{"id":"2586349287","title":"每日卖空追踪 | 维立志博-B 11月24日卖空量成交2.5万股，卖空比例为2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586349287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586349287?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973039,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月24日，跌0.49%，卖空量成交2.5万股，较上一交易日减少77.88%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2585863834","title":"创新药双周报：4-1BB：复盘历史失败原因 维立志博做对了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2585863834","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585863834?lang=zh_cn&edition=full","pubTime":"2025-11-23 00:00","pubTimestamp":1763827200,"startTime":"0","endTime":"0","summary":"目前有两款在研4-1BB双抗从设计上解决肝毒性，同时展现了惊艳的疗效，有望改写历史。MET-233i通过创新机制在Phase 1研究中单药即实现8.4%的安慰剂校正体重下降，且其约19天的半衰期为开发月度给药的固定剂量复方制剂奠定基础。这是全球首个 ADC 药物在食管癌治疗中取得 PFS/OS 双阳性结果的 III 期临床研究。创新药双周建议关注组合：康方生物、三生制药、映恩生物、信达生物、先声药业、歌礼制药、维立志博。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","LU2399975544.HKD","LU0348783233.USD","BK1161","LU0348767384.USD","LU2476274720.SGD","LU0540923850.HKD","LU0348825331.USD","LU0348827113.USD","09926","HK0000500386.USD","LU0417516571.SGD","HK0000252160.HKD","LU0417516738.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0348766576.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU0634319403.HKD","LU0348784397.USD","06978","LU2488822045.USD","LU1794554557.SGD","BK1574","LU0348735423.USD","LU0561508036.HKD","09887","LU0417516902.SGD","HK0000252152.HKD","LU2476274308.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.1186},{"period":"3month","weight":-0.2545},{"period":"6month","weight":0.4857},{"period":"ytd","weight":0.4857}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}